GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Preferred Stock

Cardax (Cardax) Preferred Stock : $0.00 Mil (As of Mar. 2021)


View and export this data going back to 2012. Start your Free Trial

What is Cardax Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Cardax's preferred stock for the quarter that ended in Mar. 2021 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Cardax's Enterprise Value for the quarter that ended in Mar. 2021 was $7.14 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Cardax's Book Value per Share for the quarter that ended in Mar. 2021 was $-14.15.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Cardax's Earnings per Share (Diluted) for the three months ended in Mar. 2021 was $-1.74.


Cardax Preferred Stock Historical Data

The historical data trend for Cardax's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardax Preferred Stock Chart

Cardax Annual Data
Trend Mar12 Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Preferred Stock
Get a 7-Day Free Trial Premium Member Only - - - - -

Cardax Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cardax Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Cardax  (OTCPK:CDXI) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Cardax's Enterprise Value for the quarter that ended in Mar. 2021 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Cardax's Book Value per Share for the quarter that ended in Mar. 2021 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Cardax's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardax Preferred Stock Related Terms

Thank you for viewing the detailed overview of Cardax's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardax (Cardax) Business Description

Traded in Other Exchanges
N/A
Address
2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
Executives
Paulson Capital Corp 10 percent owner 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc. 10 percent owner 5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc 10 percent owner 811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204

Cardax (Cardax) Headlines

From GuruFocus

Cardax Refocuses on ZanthoSyn� Consumer Health Business

By PRNewswire PRNewswire 08-31-2021

Cardax Reports 2017 Results

By PRNewswire PRNewswire 03-27-2018

Cardax Reports Q1 2019 Results

By PRNewswire PRNewswire 05-17-2019

Cardax Reports Q3 2020 Results

By PRNewswire PRNewswire 11-14-2020

Cardax Announces Interim Results from CHASE Clinical Trial

By PRNewswire PRNewswire 09-23-2019

Cardax Reports Q1 2021 Results

By PRNewswire PRNewswire 05-14-2021